Total reported value
$364.5M
Reporting period: 2026-03-31 · Number of holdings: 17
Davern Capital Partners, LP disclosed 17 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $364.5M and a quarterly turnover rate of 40.8%.
Browse other institutions with $100M to $1B AUMBrowse other institutions starting with "D"
Trim PFE
-22.0% -$6.1M
Add LLY
+228.4% $16.2M
Trim BNTX
-17.8% -$8.2M
Trim RPRX
-38.1% -$7.5M
Trim REGN
-14.5% -$5.8M
Trim ARGX
-1.8% -$4.4M
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | PFE | Pfizer INC | Stock-Healthcare | 12.28% | -4.16% | -21.95% | |
| 2 | REGN | Regeneron Pharmaceuticals | Stock-Healthcare | 9.50% | -3.58% | -14.54% | |
| 3 | INSM | Insmed INC | Stock-Healthcare | 8.19% | +8.19% | NEW | |
| 4 | IONS | Ionis Pharmaceuticals INC | Stock-Healthcare | 7.97% | +1.87% | +62.24% | |
| 5 | NTRA | Natera INC | Stock-Healthcare | 7.90% | +2.07% | +83.05% | |
| 6 | BNTX | Biontech Se-adr | Stock-Other | 7.44% | -3.99% | -17.82% | |
| 7 | ARGX | Argenx Se - Adr | Stock-Healthcare | 7.02% | -2.68% | -1.79% | |
| 8 | LLY | Eli Lilly & Co | Stock-Healthcare | 6.88% | +3.99% | +228.39% | |
| 9 | RPRX | Royalty Pharma plc | Stock-Healthcare | 6.84% | -3.66% | -38.14% | |
| 10 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 6.64% | -0.57% | -15.06% | |
| 11 | LEGN | Legend Biotech Corp-adr | Stock-Other | 6.52% | -0.91% | +24.42% | |
| 12 | MLYS | Mineralys Therapeutics INC | Stock-Other | 3.32% | +0.85% | +112.28% | |
| 13 | ABVX | Abivax Sa-adr | Stock-Other | 2.39% | +0.28% | +61.08% | |
| 14 | GENB | Generate Biomedicines INC | Stock-Other | 2.03% | +2.03% | NEW | |
| 15 | PRCT | Procept Biorobotics CORP | Stock-Other | 1.79% | +1.79% | NEW | |
| 16 | GPCR | Structure Therapeutics INC | Stock-Other | 1.67% | +1.67% | NEW | |
| 17 | VRDN | Viridian Therapeutics INC | Stock-Other | 1.62% | -1.01% | +15.61% |
Performance for Q3 2026
+3%
Performance Last 4 Quarters
-2.1%
Based on 5 months of available history
Based on 70% of reported portfolio value with available pricing
Davern Capital Partners, LP's most significant position changes for 2026-03-31: New buy: Insmed INC (INSM); New buy: Generate Biomedicines INC (GENB); Sold out: Cg Oncology INC (CGON); New buy: Procept Biorobotics CORP (PRCT); New buy: Structure Therapeutics INC (GPCR).
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | LLY | Eli Lilly & Co | +4% | +228.39% | Add |
| 2 | NTRA | Natera INC | +2.1% | +83.05% | Add |
| 3 | IONS | Ionis Pharmaceuticals INC | +1.9% | +62.24% | Add |
| 4 | MLYS | Mineralys Therapeutics INC | +0.9% | +112.28% | Add |
| 5 | ABVX | Abivax Sa-adr | +0.3% | +61.08% | Add |
| 6 | ROIV | Roivant Sciences Ltd. | -0.6% | -15.06% | Trim |
| 7 | LEGN | Legend Biotech Corp-adr | -0.9% | +24.42% | Add |
| 8 | VRDN | Viridian Therapeutics INC | -1% | +15.61% | Add |
| 9 | ARGX | Argenx Se - Adr | -2.7% | -1.79% | Trim |
| 10 | REGN | Regeneron Pharmaceuticals | -3.6% | -14.54% | Trim |
| 11 | RPRX | Royalty Pharma plc | -3.7% | -38.14% | Trim |
| 12 | BNTX | Biontech Se-adr | -4% | -17.82% | Trim |
| 13 | PFE | Pfizer INC | -4.2% | -21.95% | Trim |
| 14 | INSM | Insmed INC | — | NEW | New buy |
| 15 | GENB | Generate Biomedicines INC | — | NEW | New buy |
| 16 | CGON | Cg Oncology INC | — | EXIT | Sold out |
| 17 | PRCT | Procept Biorobotics CORP | — | NEW | New buy |
| 18 | GPCR | Structure Therapeutics INC | — | NEW | New buy |
Institutions with a similar AUM
CIK 0001946237
Total reported value
$364.7M
87 stks
2026-03-31
AUM within 0.0% of this institution
CIK 0002011149
Total reported value
$364.3M
112 stks
2026-03-31
AUM within 0.1% of this institution
CIK 0001905962
Total reported value
$364.8M
111 stks
2026-03-31
AUM within 0.1% of this institution
Institutions with overlapping top holdings
CIK 0001103887
Total reported value
$1.8B
52 stks
2026-03-31
2 of the top 5 holdings overlap, including Insmed INC
CIK 0001536411
Total reported value
$3.4B
70 stks
2026-03-31
2 of the top 5 holdings overlap, including Natera INC
CIK 0001599882
Total reported value
$810.5M
86 stks
2026-03-31
2 of the top 5 holdings overlap, including Regeneron Pharmaceuticals